MET and colonic neoplasm: Thus, our results suggested that MET activation induced by cetuximab conferred resistance to cetuximab in non-MET-amplified colon cancer cells, identifying a subset of colon cancer patients who develop cetuximab resistance in the absence of MET amplification.